# Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2016

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-Q
- Filed: 2016-08-10
- Accepted by EDGAR: Aug 10, 2016, 16:46 ET
- Period: 2016-06-30
- Accession: 0001144204-16-118057
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000114420416118057/v446124_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000114420416118057/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $234.6k | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2016-01-01 to 2016-06-30 | $234.6k | us-gaap:SalesRevenueNet |
| Research and development | 3 months, 2016-04-01 to 2016-06-30 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2016-01-01 to 2016-06-30 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 3 months, 2016-04-01 to 2016-06-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-01-01 to 2016-06-30 | $0 | us-gaap:InterestExpense |
| Net income | 3 months, 2016-04-01 to 2016-06-30 | −$3.8m | us-gaap:ProfitLoss |
| Net income | 6 months, 2016-01-01 to 2016-06-30 | −$6.3m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2016-04-01 to 2016-06-30 | −$0.46 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2016-01-01 to 2016-06-30 | −$0.77 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2016-01-01 to 2016-06-30 | −$4.0m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2016-06-30 | $8.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $8.8m | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $12.8m | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $5.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-06-30 | $6.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-06-30 | $6.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 38,263 characters.

*The following section of this Quarterly Report on Form 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Factors that may cause our actual results to differ materially from those in the forward-looking statements include those factors described in “Item 1A. Risk Factors” beginning on page 29 of our Annual Report. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 1 of this Quarterly Report on Form 10-Q.*

EyeGate Pharmaceuticals, Inc. is referred to herein as “we,” “our,” “us,” and “the Company”. Jade Therapeutics, Inc., a wholly-owned subsidiary of the Company, is referred to herein as “Jade”.

### Business Overview

We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, the Company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydration and healing properties when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical trial for its lead ocular gel product candidate for corneal epithelial defects.

Our proprietary technology, the EyeGate® II Delivery System, utilizes transscleral iontophoresis to deliver optimal therapeutic levels of drug directly into the targeted ocular tissue. It offers a potential alternative to current delivery modalities such as eye drops and ocular injections. Based on technology originating at the Bascom Palmer Eye Institute at the University of Miami, the EyeGate® II Delivery System has been used in over 2,000 clinical treatments to-date, including more than 1,300 treatments delivering our lead therapeutic candidate, EGP-437. The system utilizes a low-level electrical current to deliver a specified amount of drug for each treatment. The process involves applying an electrical current to an ionizable substance – one capable of carrying an electric charge – to increase its mobility across a biological membrane and, through electrorepulsion, drive a like-charged drug substance into the ocular tissue. Using our EyeGate® II Delivery System, treatments can be administered by a wider group of eye care practitioners. In-office preparation is simple and efficient, and can be completed by nursing or other office staff. Dosing takes approximately three minutes per eye, while total treatment time including preparation is roughly seven minutes per eye.

We are developing the EyeGate® II Delivery System and EGP-437 combination product (together, the “EGP-437 Product”) for the treatment of various inflammatory conditions of the eye, including anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, post-cataract surgery inflammation and pain, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the retina. Based on guidance provided by the FDA, the Company expects that if the ongoing confirmatory Phase 3 trial of the EGP-437 Product for the treatment of anterior uveitis meets non-inferiority criteria, data from this trial along with data from our previously completed Phase 3 trial in anterior uveitis will be sufficient to support a NDA filing. The Company also believes, based on guidance provided by the FDA, that the design of the planned confirmatory Phase 3 anterior uveitis trial for the EGP-437 Product is acceptable, and that the nonclinical work completed to date is sufficient to support a NDA filing.

The CMHA-S platform is based on hyaluronic acid (“HA”), a naturally occurring polymer that is important in many physiological processes, including wound healing, tissue homeostasis, and joint lubrication. To create hydrogels, the HA is modified to create thiolated carboxymethyl HA (“CMHA-S”) that is then crosslinked together through the thiol groups. Some products are disulfide crosslinked while others utilize a crosslinker. The crosslinking slows degradation of the HA backbone and provides a matrix for incorporating therapeutic agents. Variations in the number of thiols per molecule, the molecular weight of the polymer, the concentration of the polymer, type of crosslinking, and incorporation of other molecules provides a highly versatile platform that can be tailored to a specific application. Products can be formatted as gels, films, sponges, or powders, and crosslinking can be done in its natural environment. Our first product from the CMHA-S platform, the EyeGate Ocular Bandage Gel (the “EyeGate OBG”), is an eye drop formulation that is applied topically. The EyeGate OBG provides a thin coating to the surface of the eye, serving as a protectant to facilitate and accelerate corneal re-epithelization. The EyeGate OBG is intended for the management of corneal epithelial defects and for the acceleration of re-epithelization of the ocular surface following surgery, injection, traumatic, and non-traumatic conditions. We intend to initiate a clinical trial for the EyeGate OBG by the end of 2016.

Additionally, cross-linking allows the viscosity of the CMHA-S products to be modified to meet optimum ocular needs. The increased viscosity and non-covalent muco-adhesive interfacial forces improve residence time in the tear film, thus providing a coating that aids and promotes re-epithelization of the ocular surface via physical protection. The EyeGate OBG provides significant mechanical improvement over non-cross-linked HA products and other hydrogels by forming a degradation-resistant coating. Pilot preclinical studies suggest that this chemical modification will prolong retention time on the ocular surface, thus providing a smooth continuous clear barrier without blur, minimizing mechanical lid friction, and reducing repeat injury, which can mechanically protect the ocular surface and accelerate corneal re-epithelization.

The gel is presently available commercially as a veterinary device, manufactured by SentrX Animal Care and sold in the U.S. by Bayer Animal Health as Remend® Corneal Repair, indicated for use in the management of superficial corneal ulcers. The product has been used for 5 years in dogs, cats and horses, without any adverse effects. The composition of the veterinary product is identical to that of the EyeGate OBG.

On June 1, 2016, we announced interim data on the first 50 subjects from our Phase 1b/2a trial of our EGP-437 Product for the treatment of ocular inflammation and pain post cataract surgery. The ongoing Phase 1b/2a clinical trial is a multi-center, open-label trial enrolling up to 80 subjects who have undergone unilateral cataract extraction and implantation of a monofocal intra-ocular lens. The primary objective of this trial is to assess the safety and efficacy of iontophoretic EGP-437 in these patients following surgery and determine the optimum dose and dosing regimen to design a prospective, double-masked, randomized, controlled trial.

The Company’s acquisition of Jade in March 2016 (the “Jade Acquisition”) strengthens our market position as an integrated ocular company through the addition of a robust preclinical pipeline that complements our ongoing efforts to develop novel treatments for diseases and disorders of the eye. The Jade acquisition also expands the Company’s development focus, and creates a diversified portfolio of ocular focused assets consisting of EGP-437 and the Company’s iontophoretic delivery technology, complemented by Jade’s CMHA-S-based product pipeline. Our expanded product pipeline now includes both preclinical and clinical assets that collectively address a large market opportunity consisting of various treatments for patients suffering from eye diseases and disorders.

On July 9, 2015, we entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”), through which we granted Valeant exclusive, worldwide commercial and manufacturing rights to our EGP-437 Product in the field of anterior uveitis, as well as a right of last negotiation to license our EGP-437 Product for indications other than anterior uveitis (the “Valeant Agreement”). There are four principal R&D milestones under the Valeant Agreement: (i) the Phase 3 Clinical Trial, (ii) the Endothelial Cell Count Safety Trial (a screening tool used to verify that a patient’s cornea has an adequate endothelial cell density), (iii) the CMC Validation, and (iv) the New Drug Application, or “NDA”, filing with the FDA (collectively, the “Four Milestones”, and each individually, a “Milestone”). Under the Valeant Agreement, Valeant paid to us an initial upfront payment of $1.0 million, and we are eligible to receive milestone payments totaling up to $32.5 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the treatment of anterior uveitis. As of June 30, 2016, we have received an aggregate of $2.515 million in upfront and milestone payments from Valeant. In addition, we are eligible under the Valeant Agreement to receive royalties based on a specified percent of net sales of our EGP-437 Product for the treatment of anterior uveitis throughout the world, subject to adjustment in certain circumstances.

Throughout the Company’s history, we have not generated significant Revenue. The Company has never been profitable and, from December 26, 2004 (inception) through June 30, 2016, our losses from operations have aggregated $71.5 million. Our Net Loss was approximately $6.3 million and $4.3 million for the six months ended June 30, 2016 and 2015, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and clinical trials of and seek regulatory approval for our EGP-437 Product for the treatment of uveitis as well as other indications, or the EyeGate OBG, our lead product candidate for corneal epithelial defects, and any other product candidates we advance to clinical development. If we obtain regulatory approval for the EGP-437 Product for the treatment of uveitis, or any other indication, we expect to incur significant expenses in order to create an infrastructure to support the commercialization of the EGP-437 Product, including sales, marketing and distribution functions. Likewise, if we obtain regulatory approval for the EyeGate OBG, we expect to incur additional significant sales, marketing and distribution expenses.

The Company will need additional financing to support our continuing operations. The Company will seek to fund our operations through public or private equity, debt financings, license and development agreements, or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant Revenue to achieve profitability, and we may never do so.

The Company was formed in Delaware on December 26, 2004. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. At that time, the name of the French corporation was changed to EyeGate Pharma S.A.S. and became a subsidiary of EyeGate Pharmaceuticals, Inc. Jade was formed in Delaware on December 31, 2012. EyeGate Pharma S.A.S. and Jade are wholly-owned subsidiaries of EyeGate Pharmaceuticals, Inc.

### Financial Overview

### Revenues

To date, EyeGate has recognized limited Revenue, principally from several U.S. government grants made to Jade for ocular therapeutic research (collectively, the “U.S. Government Grants”) and from our licensing agreement with Valeant. We expect to continue to incur significant operating losses as we fund research and clinical trial activities relating to our ocular therapeutic assets, consisting of EGP-437, the Company’s iontophoretic delivery technology, and Jade’s CMHA-S-based products. There can be no guarantee that the losses incurred to fund these activities will succeed in generating Revenue.

### Research and Development Expenses

The Company incurs significant costs in funding the development of its ocular therapeutic assets, including fees to license technologies that form the basis of our product platforms. In general, we expense virtually all of our costs as incurred. We expense all research and development (“R&D”) expenses, including license fees, as they are incurred. We expect our R&D expenses to increase for the foreseeable future as we advance our ocular therapeutic products through clinical development, including the conduct of our planned clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We are unable to estimate with any certainty the costs we will incur in these processes, and we may never succeed in achieving marketing approval for our product candidates.

### General and Administrative Expenses

We expense general and administrative costs as they are incurred, and expect that these expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company and maintaining compliance with NASDAQ listing, SEC filing and other regulatory, board- and shareholder-related requirements. These increases will likely include higher consulting costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and fees associated with investor relations.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions. While our critical accounting policies are discussed in more detail in Note 2 to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the policies below are particularly important in evaluating our financial condition and results of operations.

### Accrued Research and Development Expenses

As part of the process of preparing financial statements, we are required to estimate and accrue R&D expenses. We base our expense accruals related to non-clinical development, preclinical studies, and clinical trials on our estimates of the services received and efforts expended pursuant to contracts with organizations/consultants that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts may depend on many factors, such as the successful enrollment of patients, site initiation and the completion of clinical trial milestones. Our service providers invoice us as milestones are achieved and monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of accrued R&D expenses after a reporting period.

However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies and other research activities.

### Stock-Based Compensation

We have issued options to purchase our Common Stock. We account for stock-based compensation in accordance with ASC 718, *Compensation - Stock Compensation*. ASC 718 establishes accounting for stock-based awards exchanged for employee services. Under the fair value recognition provisions of ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service/vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based payment awards require the use of highly subjective assumptions, including the expected life of the stock-based payment awards and stock price volatility.

During the six months ended June 30, 2016, we granted options to purchase 252,256 shares of our Common Stock.

### Revenue Recognition

The Valeant Agreement entitles the Company to an initial, up-front payment, which we received in 2015 and recorded as Deferred Revenue on our Balance Sheet, and certain additional payments, based on R&D progress and paid over several years. Under the Valeant Agreement, there are R&D Milestones, or deliverables, for which we receive additional payments. We receive payments both when we cross certain thresholds on the path to each Milestone (each, a “Progress Payment”), as well as once we finally achieve each Milestone. We are entitled to retain all of these payments once received. We defer all Progress Payments and capitalize these payments on our Balance Sheet as Deferred Revenue, and we recognize these payments as Revenue once we achieve the Milestone to which the Progress Payment relates. The upfront payment is recognized as Revenue ratably as we complete each of the R&D Milestones, the amount recognized being the amount of the upfront payment times the percentage represented by the proportionate share of fair value of each Milestone relative to the total fair value of the all the R&D Milestones. Accordingly, the Deferred Revenue account on our Balance Sheet is reduced as Revenue is recognized.

We receive U.S. Government Grant funds from two sources: the U.S. Department of Defense (“DoD”) and the National Science Foundation (“NSF”). We are paid by the DoD after we perform specified, agreed-upon research, and we record these grant funds as Revenue as we perform the research. We are paid by the NSF before we perform specified, agreed-upon research. These NSF funds are recorded on the Balance Sheet as Deferred Revenue when invoiced, and recognized as Revenue ratably as the research is performed, typically over a six-month period.

### Other Information

### JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the “Securities Act”), for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more, (b) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

### Results of Operations

### Comparison of Three Months ended June 30, 2016 and 2015

The following table summarizes the results of our operations for the three months ended June 30, 2016 and 2015:

|  | Three Months Ended June 30, (Unaudited) 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Collaboration Revenue | $234,600 | $- | $234,600 |
| Operating Expenses: |  |  |  |
| Research and Development | 2,481,534 | 604,108 | 1,877,426 |
| General and Administrative | 1,579,155 | 939,487 | 639,668 |
| Total Operating Expenses | (4,060,689) | (1,543,595) | (2,517,094) |
| Other Income, Net: | 2,808 | 2,242 | 566 |
| Net Loss Attributable to Common Stockholders | $(3,823,281) | $(1,541,353) | $(2,281,928) |

*Collaboration Revenue.* Collaboration Revenue was $0.235 million for the three months ended June 30, 2016, compared to $0 million for the three months ended June 30, 2015, reflecting the Jade Acquisition and the accompanying Collaboration Revenue from U.S. Government Grants.

*Research and Development Expenses.* Research and Development Expenses were $2.482 million for the three months ended June 30, 2016, compared to $0.604 million for the three months ended June 30, 2015. The increase of $1.877 million is primarily due to an increase in clinical and other activity related to the acceleration of Phase 3 clinical trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and the EyeGate OBG, as well as research expenses attributable to the Company’s EGP-437-based product pipeline and EyeGate’s CMHA-S-based product pipeline.

*General and Administrative Expenses.* General and Administrative Expenses were $1.579 million for the three months ended June 30, 2016, compared to $0.939 million for the three months ended June 30, 2015. The increase of $0.640 million was due to increases in payroll, office and other expenses as company operations have expanded with the acceleration in clinical activity related to the EGP-437 Phase 3 trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and EyeGate’s OBG, as well as the expansion of operations following the Jade Acquisition.

*Other Income, Net.* Other Income, Net was $0.003 million and $0.002 million for the three months ended June 30, 2016 and 2015, respectively, with respect to interest income that was essentially unchanged.

*Net Loss Attributable to Common Stockholders.* Net Loss Attributable to Common Stockholders of $(3.823) million for the three months ended June 30, 2016 was significantly larger than the Net Loss of $(1.541) million for the three months ended June 30, 2015, due principally to the acceleration of expenses relating to the EGP-437 Phase 3 trials, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and EyeGate’s OBG, and increased R&D Expenses, General and Administrative Expenses, and other expenses to support these activities.

### Comparison of Six Months ended June 30, 2016 and 2015

The following table summarizes the results of our operations for the six months ended June 30, 2016 and 2015:

|  | Six Months Ended June 30, (Unaudited) 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Collaboration Revenue | $234,600 | $- | $234,600 |
| Operating Expenses: |  |  |  |
| Research and Development | 3,395,506 | 925,547 | 2,469,959 |
| General and Administrative | 3,107,933 | 1,722,333 | 1,385,600 |
| Total Operating Expenses | (6,503,439) | (2,647,880) | (3,855,559) |
| Other Income (Expense), Net: | 3,125 | (1,694,559) | 1,697,684 |
| Net loss | (6,265,714) | (4,342,439) | (1,923,275) |
| Net Income Attributable to Non-Controlling Interest | - | (5,177) | 5,177 |
| Deemed Dividend on Preferred Stock | - | (8,222,008) | 8,222,008 |
| Net Loss Attributable to Common Stockholders | $(6,265,714) | $(12,569,624) | $6,303,910 |

22

### Results of Operations (continued)

*Collaboration Revenue.* Collaboration Revenue was $0.235 million for the six months ended June 30, 2016, compared to $0 million for the six months ended June 30, 2015, reflecting the Jade Acquisition and the accompanying Collaboration Revenue from U.S. Government Grants.

*Research and Development Expenses.* Research and Development Expenses were $3.396 million for the six months ended June 30, 2016, compared to $0.926 million for the six months ended June 30, 2015. The increase of $2.470 million is primarily due to the acceleration of Phase 3 clinical trials for the treatment of anterior uveitis, of the Phase 1b/2a trial for post-cataract surgery inflammation and pain, as well as of the development of EyeGate’s OBG, and development expenses attributable to the Company’s EGP-437-based product pipeline and EyeGate’s CMHA-S-based product pipeline.

*General and Administrative Expenses.* General and Administrative Expenses were $3.108 million for the six months ended June 30, 2016, compared to $1.722 million for the six months ended June 30, 2015. The increase of $1.386 million was due increases in payroll, office and other expenses as company operations have expanded with the acceleration in clinical activity related to the EGP-437 Phase 3 trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and EyeGate’s OBG, and the expansion of operations following the Jade Acquisition.

*Other Income (Expense), Net.* Other Income (Expense), Net was $0.003 million and ($1.695) million for the six months ended June 30, 2016 and 2015, respectively, which reduction was due to the occurrence of significant transaction costs relating to the Company’s IPO in the six months ended June 30, 2015 that did not recur in the six months ended June 30, 2016.

*Net Loss Attributable to Common Stockholders.* Net Loss Attributable to EyeGate Pharmaceuticals, Inc. Common Stockholders of $(6.266) million for the six months ended June 30, 2016 was significantly smaller than the Net Loss of $(12.570) million for the six months ended June 30, 2015, due principally to a charge of $8.222 million for a Deemed Dividend on Preferred Stock in the six months ended June 30, 2015, notwithstanding significantly lower Operating Expenses of $2.648 million in the six months ended June 30, 2015 compared to $6.503 million in the six months ended June 30, 2016.

### Liquidity and Capital Resources

Since becoming a public company in 2015, the Company has financed its operations from the three public offerings of our Common Stock and convertible preferred stock, and milestone payments from our Valeant License Agreement and U.S. Government Grants. Since inception through June 30, 2016, the Company raised a total of $70.400 million from such sales of our equity and debt securities, both as a public company and prior to our IPO, as well as payments received under our license agreements and U.S. Government Grants.

In March 2016, the Company issued approximately 690,000 shares of our Common Stock and paid approximately $0.300 million in Cash to fund the Jade Acquisition.

On July 9, 2015, EyeGate received the initial $1.000 million upfront payment from Valeant as provided under the Valeant Agreement. Through June 30, 2016, we have received Cash payments of $2.563 million under the Valeant Agreement, which are presented as Deferred Revenue on our Condensed Consolidated Balance Sheet. We expect to receive a Cash payment of $0.855 in the third quarter of 2016, also from the Valeant Agreement.

On May 24, 2016, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”), to create an at-the-market equity program under which we can from time to time offer and sell up to 1,319,289 shares of its Common Stock through the Sales Agent. Effective as of June 26, 2016, we halted all future offers and sales of our Common Stock pursuant to the ATM Agreement indefinitely. As of June 30, 2016, the Company had not sold any shares of Common Stock pursuant to the ATM Agreement. On June 30, 2016, the Company closed on the sale of our equity securities in connection with a registered direct offering, described below, and as a result, we are restricted from issuing any shares pursuant to the ATM Agreement for a period of 90 days following June 30, 2016.

On June 30, 2016, the Company issued 441,000 shares of Common stock and 2,776.5 shares Series A Preferred Stock, along with a concurrent private placement of warrants, with total gross proceeds of approximately $3.77 million, in a registered direct offering (the “Offering”). Concurrently with the closing of the Offering, the holder of the Series A Preferred Stock elected to convert 123.75 shares of Series A Preferred Stock into 55,000 shares of Common stock. The Company received net proceeds from the Offering, after deducting the placement agent fees and our estimated Offering expenses, of approximately $3.4 million.

At June 30, 2016, the Company had cash and cash equivalents totaling $8.026 million.

### Results of Operations (continued)

The following table sets forth the primary sources and uses of cash for the six months ended June 30, 2016 and 2015:

|  | Six Months Ended June 30, 2016 | 2015 |
| --- | ---: | ---: |
| Cash Used in Operating Activities | $(4,028,543) | $(2,741,052) |
| Cash Provided by (Used in) Investing Activities | 160,746 | (20,000) |
| Cash Provided by Financing Activities | 3,501,142 | 3,788,439 |

### Comparison of Six Months Ended June 30, 2016 and 2015

*Operating Activities.* Cash Used in Operating Activities was $4.029 million for the six months ended June 30, 2016, compared to Cash Used in Operating Activities of $2.741 million for the six months ended June 30, 2015. The primary use of Cash was to fund operating losses of $6.266 million in 2016, offset by the positive impact of receiving Cash payments from the Valeant Agreement and the U.S. Government Grants, some of which is classified as Deferred Revenue on the Balance Sheet, and some of which is recognized as Revenue currently.

*Investing Activities.* On March 7, 2016, we acquired Jade Therapeutics, Inc., a Common Stock and Cash transaction that required the use of $0.300 million in Cash.

*Financing Activities.* We generated approximately $3.501 million in Cash from financing activities in the first half of 2016 upon the closing of the Offering on June 30, 2016.

### Funding Requirements and Other Liquidity Matters

Our EGP-437 Combination Product and our CMHA-S-based product pipeline are still in various stages of clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

- seek marketing approval for our EGP-437 Combination Product and our CMHA-S-based products;
- establish a sales and marketing infrastructure to commercialize our EGP-437 Combination Product and our CMHA-S-based products in the United States, if approved;
- add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a Common Stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including our EGP-437 Product and our CMHA-S-based products, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market the EGP-437 Product and CMHA-S-based products that we would otherwise prefer to develop and market ourselves.

Based on our cash on hand at June 30, 2016, we will have sufficient cash to fund planned operations for approximately 9 to 12 months. However, the acceleration or reduction of cash outflows by management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, we will need to raise additional capital through debt and/or equity financing, or access additional funding through grants. Although we completed the IPO and follow-on offering, additional capital may not be available on terms favorable to EyeGate, if at all. On May 6, 2016, the SEC declared effective our registration statement on Form S-3, registering a total of $100,000,000 of our securities for sale to the public in what is known as a “shelf offering”. We do not know if our future offerings pursuant to our shelf registration statement will succeed. Accordingly, no assurances can be given that management will be successful in these endeavors. These conditions raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.

### Off-Balance Sheet Arrangements

We had no off-Balance Sheet arrangements as of June 30, 2016.

### Contractual Obligations

The following table summarizes our contractual obligations as of June 30, 2016:

|  | Total | Less than 1 Year | 1-3 Years | More than 3 Years |
| --- | ---: | ---: | ---: | ---: |
| Operating Leases 1 | $316,582 | $155,284 | $161,298 | $- |
| Licensing Agreements 2 | 90,000 | 27,500 | 37,500 | 25,000 |
| Purchase Obligations 3 | 2,366,902 | 2,366,902 | - | - |
| Total 4 | $2,773,484 | $2,549,686 | $198,798 | $25,000 |

1 Operating Lease obligations reflect our obligation to make payments in connection with leases for our office space.

2 Licensing Agreement obligations represent our commitments under license agreements, including those made by the Company under its license agreements with the University of Miami School of Medicine and the University of Utah Research Foundation.

3 Purchase Obligations relate to a Master Service Agreement with a contract research organization (“CRO”). The CRO will provide clinical research services for Phase 3 trial in patients with non-infectious anterior segment uveitis.

4 This table does not include (a) anticipated expenditures under supply agreements for periods for which we are not yet bound under binding purchase orders, (b) contracts that are entered into in the ordinary course of business that are not material in the aggregate in any period presented above.

## Controls and procedures

As filed, 2,478 characters.

### Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the President and Chief Executive Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Quarterly Report on the Form 10-Q, our management, under the supervision and with the participation of our President and Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2016. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and our management necessarily was required to apply its judgment in evaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our President and Chief Executive Officer and our Chief Financial Officer have concluded that they believe that our disclosure controls and procedures were effective as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

In connection with the acquisitions of Jade in March 2016, we began implementing standards and procedures at Jade, including establishing controls over accounting systems and establishing controls over the preparation of financial statements in accordance with generally accepted accounting principles to ensure that we have in place appropriate internal control over financial reporting at Jade. We are continuing to integrate the acquired operations of Jade into our overall internal control over financial reporting process.

These changes to the Company’s internal control over financial reporting that occurred during the most recent quarter ended June 30, 2016 have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 553 characters.

Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016, and Item 1A of Part I of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 13, 2016, contain risk factors identified by the Company. There have been no material changes to the risk factors we previously disclosed. Our operations could also be affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.

Filed Aug 10, 2016.
Source: SEC EDGAR, the filing index for accession 0001144204-16-118057. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
